Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Published:1999-12-01 Issue:26 Volume:42 Page:5369-5389
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hennequin Laurent F.¹,Thomas Andrew P.¹,Johnstone Craig¹,Stokes Elaine S. E.¹,Plé Patrick A.¹,Lohmann Jean-Jacques M.¹,Ogilvie Donald J.¹,Dukes Mike¹,Wedge Steve R.¹,Curwen Jon O.¹,Kendrew Jane¹,Lambert-van der Brempt Christine¹

Affiliation:

1. AstraZeneca, Zeneca Pharma, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims Cedex 2, France, and AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm990345w

Reference72 articles.

1. Angiogenesis in cancer, vascular, rheumatoid and other disease

2. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth.

3. Vascular permeability factor (VPF, VEGF) in tumor biology

Cited by 248 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies;European Journal of Medicinal Chemistry;2023-11

2. RET/Multikinase Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

3. The Structure–property Relationships of Clinically Approved Protein Kinase Inhibitors;Current Medicinal Chemistry;2023-07

4. A Review on Inhibitory Action of Tyrosine Kinase Inhibitors (TKI) by Curbing the ATP-Tyrosine Kinase Interactions;Current Signal Transduction Therapy;2023-07

5. Vandetanib;Profiles of Drug Substances, Excipients and Related Methodology;2023